Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems.
Ontology highlight
ABSTRACT: Adverse drug reactions (ADRs) restrict the maximum doses applicable in chemotherapy, which leads to failure in cancer treatment. Various approaches, including nano-drug and prodrug strategies aimed at reducing ADRs, have been developed, but these strategies have their own pitfalls. A renovated strategy for ADR reduction is urgently needed. Here, we employ an enzymatic supramolecular self-assembly process to accumulate a bioorthogonal decaging reaction trigger inside targeted cancer cells, enabling spatiotemporally controlled, synergistic prodrug activation. The bioorthogonally activated prodrug exhibits significantly enhanced potency against cancer cells compared with normal cells. This prodrug activation strategy further demonstrates high tumour inhibition efficacy with satisfactory bioco
SUBMITTER: Yao Q
PROVIDER: S-EPMC6261997 | biostudies-literature | 2018 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA